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ISSContext: Recent studies have highlighted the increased risk of adverse outcomes
among older patients on antiretroviral therapy (ART). We report on the associations
between older age and adverse outcomes in HIV/AIDS antiretroviral programmes across
17 programmes in sub-Saharan Africa.
Methods: We included data from nine countries: Central African Republic, Coˆte
d’Ivoire, Democratic Republic of Congo, Ethiopia, Nigeria, Republic of Congo,
Uganda, Zambia and Zimbabwe. We describe survival probability for progression to
death and loss to follow-up for patients initiating ART aged less than 50 years and at least
50 years. Multivariate Cox proportional hazards models were used to assess the
association between age (15–39, 40–49, 50–59, 60–69 and 70–94 years) and adverse
outcomes adjusting for confounders identified a priori.
Results: Our analysis included 17 561 patients followed for a median of 12 months. The
majority (65%) were female and 6672 (38%) were severely immunosuppressed at
baseline. Median age at ART initiation was 36.0 years (interquartile range 30.1–42.8);
11.4% of patients were aged at least 50 years. Median gain in CD4 cell count at 6 and 12
months was significantly higher in patients less than 50 years old compared with those
at least 50 years (134 vs. 112 cells/ml at 6 months; 170 vs. 139 cells/ml at 12 months;
both P<0.001). In multivariate analysis, there was a significant increased risk of
mortality beyond 3 months after ART initiation in all age groups of at least 40 years
of age compared with less than 40 years [40–49 years adjusted hazard ratios (aHRs)
1.59, P<0.001; 50–59 years aHR 1.58, P¼0.002; 60–69 years aHR 2.63, P<0.001;
70–94 years aHR 3.64, P¼0.004).
Conclusion: Older age groups represent an important proportion of the overall treat-
ment cohort in these sub-Saharan Africa programmes, and risk of mortality increased as
age increased. Future research should be directed at further understanding the reasons
for higher mortality, and defining simple interventions that are feasible in highly under-
resourced settings to allow for adapted follow-up and care approaches for older age
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Increased access to antiretroviral therapy (ART) in
resource-limited settings over the last decade has resulted
in substantial reductions in AIDS-related illness and death
[1,2] for people living with HIV/AIDS.
Concern about heightened vulnerability within specific
age groups has tended to focus on the lower extreme,
particularly infants and children [3], and more recently
adolescents [4]. Vulnerability at the other age extreme has
received less attention. The need to focus on older age
groups has recently been highlighted by reports from sub-
Saharan Africa showing higher mortality in people aged
50 years and older [5–9]. This has led to calls for greater
attention to be paid to the specific vulnerabilities of older
populations in HIV/AIDS programmes [10].
In this study, we report on the association between older
age and adverse outcomes in HIV/AIDS programmes
across nine countries in sub-Saharan Africa.Methods
This analysis is based on data from 17 programmes from
nine countries in sub-Saharan Africa: Central African
Republic, Coˆte d’Ivoire, Democratic Republic of
Congo, Ethiopia, Nigeria, Republic of Congo, Uganda,
Zambia and Zimbabwe. At each site, data were routinely
collected by clinical staff using standardized forms and
entered into an electronic database (FUCHIA, Epicentre,
Paris, France). This database has been described in detail
elsewhere [11]. Data for all adult patients (15 years or
older) initiating ART between September 2003 and
March 2010 were included in this study.
Descriptive analyses were based on percentages and
frequencies for categorical variables and medians and
interquartile ranges (IQRs) for continuous variables.
Baseline characteristics were described for the cohort
overall and separately for patients aged less than 50 years
and at least 50 years. Continuous variables were assessed
for skew and as all demonstrated nonnormality they were
compared using theWilcoxon rank-sum test. Proportions
were compared using the x2-test.
We used Kaplan–Meier estimates to describe the
cumulative probability of progression to death and loss
to follow-up for patients aged less than 50 years and at
least 50 years across all projects. Loss to follow-up was
defined as missing a scheduled appointment by 2 months
or more. Multivariate Cox proportional hazards models
were used to model the association between age and
adverse outcomes (death and loss to follow-up). Age was
assessed as a categorical variable (15–39, 40–49, 50–59,
60–69 and 70–94 years). These models adjusted for thepyright © Lippincott Williams & Wilkins. Unauthofollowing potential confounders defined a priori: sex (male
or female), BMI (kg/m2) at ART initiation, clinic setting
(urban or rural), tuberculosis (TB) at ART initiation and
severe immunosuppression at ART initiation (defined as
WHO stage IVor CD4 cell count100 cells/ml). Models
were segmented by time of follow-up (mortality >0–3
and >3–42 months of follow-up; loss to follow-up
>0–12, >12–24 and >24–42 months of follow-
up) and hazard proportionality assessed by analysis of
scaled Schoenfeld residuals. We performed sensitivity
analyses to assess the potential influence of a specific
programme on the overall mortality estimate by leaving
out each programme in separate regressions, and assessing
the potential effect of misclassification of mortality among
patients lost to follow-up using a competing risks
framework [12]. All reported P values are exact and
two-tailed, and for each analysis P< 0.05 was considered
significant. All analyses were carried out in STATA 10.1
and 11.0 (StataCorp, College Station, Texas, USA).
The analysis was based on routine clinical data; therefore,
ethical review and individual patient consent were not
sought. All patient information was entered into a
database using coded identification numbers, and no
information that could reveal patient identity was entered
into the databases.Results
Characteristics of included population
We included 17 561 patients who were followed on ART
for a median of 12 months, and a median ART start date
of 30 October 2007. The majority (65%) were female,
and 6672 (38%) were considered severely immuno-
suppressed at baseline (Table 1). Median age at ART
initiation was 36.0 years (IQR 30.1–42.8). Most patients
(65.8%) were aged less than 40 years, whereas 3995
patients (22.8%) were aged 40–49 years, 1566 patients
(8.9%) were aged 50–59 years, 367 patients (2.1%) were
aged 60–69 years and 78 patients (0.44%) were aged 70–
94 years. The proportion of patients aged at least 50 years
was similar across countries (Table 2).
More adult patients aged less than 50 years were female
(66 vs. 51%; P< 0.001), had a diagnosis of TB at ART
initiation (8 vs. 6%; P< 0.001), and were treated in an
urban clinic setting (45 vs. 40%; P< 0.001) than patients
aged at least 50 years (Table 1). Patients in both age groups
were recorded as having similar rates of severe
immunosuppression (38 vs. 37%; P¼ 0.14).
Immune restoration, mortality and loss to
follow-up
Patients were followed for an average of 1 year (IQR
0.34–1.92 years) with patients aged less than 50 followed
for slightly less time than those at least 50 years (1.00 vs.rized reproduction of this article is prohibited.
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Table 1. Baseline characteristics of patients at antiretroviral therapy initiation.
15–49 years (n¼15584) 50–95 years (n¼1977) P-value Total
Female, n (%) 10350 (66) 1010 (51) <0.001 11360 (65)
Current tuberculosis diagnosis, n (%) 1302 (8) 121 (6) <0.001 1423 (8)
BMI, median (IQR) 19.8 (17.6, 22.2) 19.9 (17.9, 22.5) 0.021 19.8 (17.7, 22.2)
CD4M, median (IQR) (n¼12143) 139 (65, 205) 139 (71, 201) 0.54 139 (67, 204)
CD4 <100 n (%) 3968 (37%) 497 (36%) 0.30 4465 (37%)
CD4 100 <200 n (%) 3949 (37%) 542 (39%) 4491 (37%)
CD4 200 <350 n (%) 2373 (22%) 302 (22%) 2675 (22%)
CD4 350 n (%) 462 (4%) 50 (4%) 512 (4%)
Clinical WHO stage 4, n (%) 2897 (19) 309 (16) 0.001 3206 (19)
Clinical WHO stage 1–3, n (%) 12334 (81) 1619 (84) 13953 (81)
Severe immunosuppressiony, n (%) 5951 (38) 721 (37) 0.14 6672 (38)
Programme in an urban setting, n (%) 7069 (45) 791 (40) <0.001 7860 (45)
IQR, interquartile range. MCD4 from up to 3 months before up until ART initiation available for 69% patients (n¼10752) aged less than 50 years,
70% patients (n¼1391) aged at least 50 years. ySevere immunosuppression: WHO stage IV or CD4 cell count 100 cells/ml.1.08 years, P¼ 0.007). The crude mortality rate for
patients aged at least 50 years was significantly higher than
for those aged less than 50 years [rate ratio (RR) 1.22,
95% confidence interval (CI) 1.03–1.43, P¼ 0.016],
whereas the rate of loss to follow-up was not significantly
different (RR 1.07, 95% CI 0.96–1.18, P¼ 0.19). The
median gain in CD4 cell count at 6 and 12 months was
significantly higher in patients less than 50 years old
compared with those at least 50 years (134 vs. 112 at
6 months; 170 vs. 139 at 12 months; both P< 0.001).
Only 28 and 21% of patients overall (similar by age group)
had CD4 cell count measurements at both baseline and
6 or 12 months, respectively, and although most variables
differed between those who did and did not have CD4
cell count measurements, there was no significant
difference in median age (results not shown).
Cox proportional hazards analysis found that all patients
aged at least 40 years were at increased mortality risk from
more than 3 to 42 months on ARTafter adjusting for sex,
current TB, BMI, severe immunosuppression and clinicCopyright © Lippincott Williams & Wilkins. Unaut
Table 2. Age distribution by project location with effect of leaving each
increase.
15–49 years
Abdurafi, Ethiopia 376
Baraka, Democratic Republic of Congo (DRC) 150
Boguila, Central African Republic 171
Bukavu, DRC 1409
Danane, Coˆte d’Ivoire 567
Dubie, DRC 84
Epworth, Zimbabwe 3922
Gweru, Zimbabwe 4644
Humera, Ethiopia 838
Kindamba, Republic of Congo (RoC) 10
Kitgum, Uganda 222
Kinkala, RoC 49
Kilwa, DRC 36
Lagos, Nigeria 1738
Mindouli, RoC 203
Nchelenge, Zambia 1139
Walikale, DRC 26
Total 15584
aHR, adjusted hazard ratio; CI, confidence interval.setting [40–49 years: adjusted hazard ratio (aHR) 1.59,
95% CI 1.29–1.96, P< 0.001; 50–59 years: aHR 1.58,
95% CI 1.19–2.11, P¼ 0.002; 60–69 years: aHR 2.63,
95% CI 1.66–4.16, P< 0.001; 70–94 years: aHR 3.64,
95% CI 1.51–8.77, P¼ 0.004; Table 3; Fig. 1a]. In
addition, there was a significantly increased risk of
mortality in those aged 70–94 years compared with
patients aged 15–39 years during the first 3 months on
ART (aHR 3.18, 95% CI 2.12–4.77; P< 0.001). Severe
immunosuppression at ART initiation was most strongly
associated with mortality (>0–3 months follow-up: aHR
2.19, 95% CI 1.83–2.63, P¼ 0.008; >3–42 months
follow-up: aHR 1.83, 95% CI 1.52–2.21, P< 0.001),
and each unit increase in BMI reduced risk of
mortality (aHR 0.88 and 0.91 for >0–3 months and
>3–42 months follow-up, respectively, P< 0.001).
Rural clinic setting was protective against mortality in
the first 3 months of ART (aHR 0.80, 95%CI 0.68–0.95,
P¼ 0.009) but a risk thereafter (aHR 1.27, 95% CI 1.05–
1.52, P¼ 0.013). Conversely, increasing age was not
associated with risk of loss to follow-up in any of thehorized reproduction of this article is prohibited.
project out on mortality adjusted hazard ratio for age per 10 year
50–95 years Total aHR (95% CI) P value
20 (5.0%) 396 1.14 (1.07, 1.21) <0.001
23 (13.3%) 173 1.14 (1.08, 1.21) <0.001
13 (7.1%) 184 1.15 (1.09, 1.22) <0.001
167 (10.6%) 1576 1.16 (1.09, 1.23) <0.001
46 (7.5%) 613 1.15 (1.09, 1.22) <0.001
11 (11.6%) 95 1.15 (1.08, 1.21) <0.001
444 (10.2%) 4366 1.12 (1.06, 1.19) <0.001
832 (15.2%) 5476 1.12 (1.05, 1.20) <0.001
56 (6.3%) 894 1.14 (1.08, 1.21) <0.001
13 (56.5%) 23 1.15 (1.09, 1.22) <0.001
32 (12.6%) 254 1.14 (1.08, 1.21) <0.001
2 (3.9%) 51 1.14 (1.08, 1.21) <0.001
5 (12.2%) 41 1.14 (1.08, 1.21) <0.001
180 (9.4%) 1918 1.15 (1.08, 1.22) <0.001
19 (8.6%) 222 1.15 (1.08, 1.21) <0.001
111 (8.9%) 1250 1.15 (1.08, 1.22) <0.001
3 (10.3%) 29 1.14 (1.08, 1.21) <0.001
1977 (11.3%) 17561 1.14 (1.08, 1.21) <0.001
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Table 3. Unadjusted and adjusted risk of death.
>0–3 months of follow-up >3–24 months of follow-up
HR (95% CI) P value aHR (95% CI) P value HR (95% CI) P value aHR (95% CI) P value
AgeM
15–39 years 1 1 1 1
40–49 years 1.17 (0.98–1.39) 0.09 1.21 (1.00–1.46) 0.050 1.53 (1.26–1.85) <0.001 1.59 (1.29–1.96) <0.001
50–59 years 1.12 (0.83–1.51) 0.45 1.16 (0.83–1.63) 0.39 1.53 (1.18–1.99) 0.001 1.58 (1.19–2.11) 0.002
60–69 years 1.22 (0.77–1.95) 0.39 1.44 (0.89–2.31) 0.14 2.76 (1.84–4.14) <0.001 2.63 (1.66–4.16) <0.001
70–94 years 2.35 (1.36–4.05) 0.002 3.18 (2.12–4.77) <0.001 3.49 (1.60–7.62) 0.002 3.64 (1.51–8.77) 0.004
Sex
Female 1 1 1 1
Male 1.33 (1.14–1.54) <0.001 1.20 (1.01–1.41) 0.035 1.34 (1.13–1.59) 0.001 1.02 (0.84–1.22) 0.87
Current TB diagnosisM
No 1 1 1 1
Yes 1.25 (0.99–1.60) 0.065 1.05 (0.81–1.34) 0.72 1.46 (1.11–1.92) 0.006 1.34 (0.99–1.80) 0.055
BMIM (per 1 kg/m2 increase) 0.86 (0.84–0.88) <0.001 0.88 (0.86–0.90) <0.001 0.89 (0.86–0.92) <0.001 0.91 (0.88–0.94) <0.001
Severe immunosuppressionM
No 1 1 1 1
Yes 2.81 (2.40–3.29) <0.001 2.19 (1.83–2.63) 0.008 2.09 (1.77–2.48) <0.001 1.83 (1.52–2.21) <0.001
Setting
Urban 1 1 1 1
Rural 1.00 (0.86–1.17) 1.00 0.80 (0.68–0.95) 0.009 1.43 (1.21–1.70) <0.001 1.27 (1.05–1.52) 0.013
Schoenfelds P 0.83 0.23
Age categorized for patients with >0–3 months or >3–42 months of follow-up. ART, antiretroviral therapy; CI, confidence interval; HR, hazard
ratio; TB, tuberculosis. MAt ART initiation.periods of follow-up assessed after adjusting for sex,
current TB, BMI, severe immunosuppression and clinic
setting (Table 4; Fig. 1b). The most significant factor
associated with loss to follow-up was the clinic being in a
rural setting, with risk increasing with greater follow-up
time (Table 4).
The association between increasing age and mortality in
the adjusted model was robust to leaving out any single
country (Table 2), and a regression that assessed the
potential for loss to follow-up as a competing risk
(subhazard ratio 1.15, 95% CI 1.08–1.21).
All of the models displayed proportional hazards except for
loss to follow-up up until 12 months on ART (Schoenfeld
residual P¼ 0.002, Table 4), primarily because of the
BMI variable, even after applying a range of statistical
contingencies to attempt to obtain proportionality,
including categorization, transformation, removal of data
outliers and assessment of possible interactions.Discussion
HIV/AIDS has resulted in a dramatic decline in life
expectancy in sub-Saharan Africa, [13] but with ART,
people living with HIV/AIDS can enjoy almost normal
life expectancy [14]. The neglect of older age groups in
the HIV/AIDS response in sub-Saharan Africa is partly
due to a perception that populations in the most affected
countries are unlikely to achieve old age anyway and so a
focus on younger patients represents a more reasonablepyright © Lippincott Williams & Wilkins. Unauthopublic health approach. However, our study shows that
older age groups represent an important proportion of the
overall ART population. More than one in 10 people on
ART in this study were found to be aged 50 years or over,
a proportion consistent across most of the nine sub-
Saharan Africa countries under review.
Previous studies have reported that people aged 50 or over
were at higher risk of mortality compared with younger
adults [5–7]. In this study, we found that mortality risk
increased as age increased after 3 months on ART,
suggesting that a simple age cut-off may not be sufficient
for defining older groups at heightened risk of death.
In developed countries, the increased risk of death among
HIV patients in older age groups is explained by the
increased risk of development of non-AIDS-defining
illnesses such as cardiovascular and liver disease, renal
impairment and malignancies [15]. A recent study from
Botswana found increased risk of non-AIDS-defining
illnesses among higher age groups, with standardized rates
higher than reported in the United States [16]. Although
this is likely to explain some of the excess mortality
observed in our cohorts, it is important to note that older
age groups are also at greater risk of infectious diseases,
particularly TB, as a result of declines in immunity
associated with older age [17].
The reason for higher mortality among older people with
HIV/AIDS is multifactorial, with the natural aging
process, immune senescence, antiretroviral drug toxicities
and HIV infection all suggested to play a role [18,19]. We
found that patients aged at least 50 years had a significantlyrized reproduction of this article is prohibited.
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(b)
Number at risk
0Years on ART 1 2 3
15-39 y 11121 5646 2543 589
40-49 y 3874 2090 1020 300
50-50 y 1518 852 418 107
60-69 y 356 172 73 22
70-94 y 73 33 9 2
Crude mortality rate
15-39 years: 53.9/1000 person years (95% CI 50.1-58.0)
40-49 years: 65.7/1000 person years (95% CI 59.0-73.1)
50-59 years: 57.5/1000 person years (95% CI 48.0-68.9)
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Years on ART
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50-59 years 60-69 years
70-94 years
Cox proportional hazards regression - mortality
60-69 years: 104.7/1000 person years (95% CI 77.9-140.7)
70-94 years: 155.5/1000 person years (95% CI 88.3-273.8)
Crude loss rate
15-39 years: 171.4 / 1000 person years (95% CI 164.5-178.5)
40-49 years: 139.6 / 1000 person years (95% CI 129.7-150.2)
50-59 years: 160.8 / 1000 person years (95% CI 144.4-179.2)
60-69 years: 223.6 / 1000 person years (95% CI 182.7-273.7)
70-94 years: 233.3 / 1000 person years (95% CI 147.0-370.2)
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Analysis time
15-39 years 40-49 years
50-59 years 60-69 years
70-94 years
Cox proportional hazards regression - loss to follow-up
Fig. 1. Cox proportional hazards regression plots. Plots of the adjusted risk of (a) death and (b) loss to follow-up after initiation of
antiretroviral therapy.lower CD4 gain at 6 and 12 months on ART, a finding
consistent with those from a large observational cohort
study from 33 European cohorts which found that the
probability of immunological response reduced in those
aged 60 years or older [20]. This gives further cause for
concern about potential vulnerability to incident
opportunistic infections and suggests a need for rapid
ART initiation as soon as clinically eligible.Copyright © Lippincott Williams & Wilkins. UnautOur results are based on data pooled from different
programmes in which HIV care was provided both as a
disease-specific programme and integrated into general
healthcare, in urban and rural areas and across a number of
countries. This allows some confidence in the general-
izability of our findings to other programmes in sub-
Saharan Africa. Leaving out any single country did not
importantly influence the role of age on mortality. Wehorized reproduction of this article is prohibited.
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Association between age and outcomes on ART Greig et al. S37were able to control for a number of patient and
programme-level variables, but cannot exclude the
possibility of residual confounding. Despite various
attempts to obtain proportionality, one of the Cox
hazards models did not adhere to the assumption of
proportional hazards; however, BMI was retained in the
model as a clinically important factor related to poor
outcomes. The likely effect of a nonproportional
predictor is that the power of the test for this variable
is reduced, such that any association may be missed, and
the concurrent model predictors that do satisfy propor-
tionality also suffer from decreased power associated with
a poorer overall model fit [21]. Finally, we were unable to
report on a number of important variables due to the
limits of routine programme reporting. In common with
reports from other routine programmes in sub-Saharan
Africa [22], CD4 cell counts were not available for a
substantial number of patients. Thus, we are unable to
report on the association between excess mortality and
age-related decline in immune status; nevertheless, higher
mortality at older age groups was still seen after
controlling for a composite measure of immunosuppres-
sion combining CD4 cell count andWHO stage. Specific
causes of death could also not be reported because this was
not routinely reported and links to death registries were
not established in these settings. We could not assess
association of HIV status and expected risk of mortality
with age in these settings, as data was from routine
monitoring of dedicated HIV programmes.
In conclusion, this study provides further evidence that
older age groups are a vulnerable group in ART
programmes and suggests that, although it is important
to identify groups in need of more careful follow-up and
earlier initiation on ART, the application of crude age
categories may result in patients at higher risk being
overlooked. Future research is now needed to understand
the reasons for higher mortality in older age groups, and
defining simple interventions that are feasible in highly
under-resourced settings to allow for adapted follow-up
and care approaches for older age groups.Acknowledgements
The authors would like to thank Leslie Shanks for
encouraging comments on an earlier draft.
Conflicts of interest
There are no conflicts of interest.References
1. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM,
Lambert PC, et al. Changes in the risk of death after HIV
seroconversion compared with mortality in the general popu-
lation. JAMA 2008; 300:51–59.Copyright © Lippincott Williams & Wilkins. Unaut2. Herbst AJ, Cooke GS, Barnighausen T, KanyKany A, Tanser F,
Newell ML. Adult mortality and antiretroviral treatment roll-
out in rural KwaZulu-Natal, South Africa. Bull World Health
Organ 2009; 87:754–762.
3. Davies MA, Egger M, Keiser O, Boulle A. Paediatric antiretro-
viral treatment programmes in sub-Saharan Africa: a review of
published clinical studies. Afr J AIDS Res 2009; 8:329–338.
4. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer
A, et al. Survival of HIV-infected adolescents on antiretroviral
therapy in Uganda: findings from a nationally representative
cohort in Uganda. PLoS One 2011; 6:e19261.
5. Negin J, Wariero J, Cumming RG, Mutuo P, Pronyk PM. High
rates of AIDS-related mortality among older adults in rural
Kenya. J Acquir Immune Defic Syndr 2010; 55:239–244.
6. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M,
Mathee S, et al. Seven-year experience of a primary care
antiretroviral treatment programme in Khayelitsha, South
Africa. AIDS 2010; 24:563–572.
7. Bakanda C, Birungi J, Mwesigwa R, Ford N, Cooper CL,
Au-Yeung C, et al. Association of aging and survival in a large
HIV-infected cohort on antiretroviral therapy. AIDS 2011;
25:701–705.
8. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association
of age with mortality and virological and immunological re-
sponse to antiretroviral therapy in rural South African adults.
PLoS One 2011; 6:e21795.
9. Negin J, van Lettow M, Semba M, Martiniuk A, Chan A,
Cumming R. Antiretroviral treatment outcomes among older
adults in Zomba District, Malawi. PLOS One 2011; 6:e26546.
10. Mills EJ, Rammohan A, Awofeso N. Ageing faster with AIDS in
Africa. Lancet 2011; 377:1131–1133.
11. FUCHIA: a free computer program for the monitoring of HIV/
AIDS medical care at the population level. In: International
Conference on AIDS; July 2002; Epicentre, Paris, France.
[Abstract C11029]
12. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: com-
peting risks and multistate models. Stat Med 2007; 26:2389–
2430.
13. Cotton D. Life expectancy in Africa: back to the future? Ann
Intern Med 2011; 155:265–266.
14. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al.
Life expectancy of persons receiving combination antiretrovir-
al therapy in low-income countries: a cohort analysis from
Uganda. Ann Intern Med 2011; 155:209–216.
15. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death
among persons with AIDS in the era of highly active antire-
troviral therapy: New York City. Ann Intern Med 2006;
145:397–406.
16. Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF,
Kipp AM, et al. Non-AIDS-defining events among HIV-1-
infected adults receiving combination antiretroviral therapy
in resource-replete versus resource-limited urban setting.AIDS
2011; 25:1471–1479.
17. Schaaf HS, Collins A, Bekker A, Davies PD. Tuberculosis at
extremes of age. Respirology 2010; 15:747–763.
18. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne
FM, et al. Aging and infectious diseases: workshop on HIV
infection and aging: what is known and future research direc-
tions. Clin Infect Dis 2008; 47:542–553.
19. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P,
et al. Immunologic and clinical responses to highly active
antiretroviral therapy over 50 years of age. Results from the
French Hospital Database on HIV. AIDS 2004; 18:2029–2038.
20. Sabin CA, Smith CJ, d’Arminio Monforte A, Battegay M,
Gabiano C, Galli L, et al., Collaboration of Observational
HIV Epidemiological Research Europe (COHERE) Study Group.
Response to combination antiretroviral therapy: variation by
age. AIDS 2008; 22:1463–1473.
21. Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V,
Mathoulin-Pelissier S. Variables with time-varying effects
and the Cox model: some statistical concepts illustrated with
a prognostic factor study in breast cancer. BMC Med Res
Methodol 2010; 10:20.
22. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A,
et al. Antiretroviral therapy in resource-limited settings 1996 to
2006: patient characteristics, treatment regimens and moni-
toring in sub-Saharan Africa, Asia and Latin America. TropMed
Int Health 2008; 13:870–879.horized reproduction of this article is prohibited.
